
    
      This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for
      the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age
      or older. This study is designed to further characterize the safety profile and gather
      additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or
      cellulitis/erysipelas.
    
  